A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

Part of paid clinical trials in Chino, California.

Sponsor
Alkermes, Inc.
Study ID
NCT07755410
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Attention Deficit Disorder With Hyperactivity (ADHD)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ALKS 7290 — DRUG
    ALKS 7290 tablets taken daily, orally, for 4 weeks
  • Placebo — DRUG
    Placebo capsule taken daily

Study Details

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

Key Dates

First listed
Aug 10, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
312 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Level 1
  • Experimental: Dose Level 2
  • Experimental: Dose Level 3
  • Placebo Comparator: Placebo
    Placebo capsule taken daily

Primary Outcome Measure

Change from Baseline to Week 4 in Attention Deficit Disorder Investigator Symptom Rating Scale (AISRS) total score [ Time Frame: Baseline to Week 4 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Alkermes Investigator SiteChinoCalifornia91710-
Alkermes Investigator SiteMaitlandFlorida32751-

Find similar trials in Chino, CA

By research site
Alkermes Investigator Site· Chino, CAAlkermes Investigator Site· Maitland, FL

Related Studies